Skip to main content

Providing the latest key information from the Government and professional regulated bodies within the industry as well as our tips.

Last Updated: Tuesday 28th July 2020

FACE MASKS | HAND SANITISERS | GLOVES | APRONS

STAY SAFE DURING COVID-19

Due to government instructions, all personal protective equipment is currently VAT Free

Find out when and how you can re-open your clinic safely

Government Guidance

Aesthetics Guidelines

Government Guidelines

Downloadable Resources

Public Health England & NHS Resources on COVID-19 Prevention

Finance

Patient

Clinic

Why not consider COVID-19 testing opportunities for your clinic?

This in-vitro diagnostic device (IVD) is for healthcare professional use only and not regulated for home use.

Yes, this rapid point-of-care COVID-19 Antibody Test that we are supplying has been MHRA approved to be supplied to healthcare professionals to be used in a professional capacity only. The MHRA requires all manufacturers of professional use COVID-19 Antibody Tests to contact them so that they can advise if a testing product can be placed on the UK market.

It is important to note that currently, the MHRA have not approved any home use antibody tests and therefore these tests are to be used in a professional capacity only, ensuring this test is carried out by a trained professional helps ensure that the patients’ blood sample is taken safely, the test results are interpreted correctly and the appropriate follow-up guidance is provided by the healthcare professional to the patient.

This rapid point-of-care antibody finger-prick blood test detects two types of antibodies - IgG (past infection) and IgM (current/recent infection).

  • Clinical Sensitivity (accuracy for COVID-19 antibody detection) – 98.66%*
  • Clinical Specificity – 99.82%*
  • Rapid result with simple finger-prick in approximately 10 minutes.
  • Easy on-site testing for yourself, your staff and your patients.
  • CE certified.
  • MHRA approved for sale and healthcare professional use.

*Clinical Sensitivity and Specificity based on clinical data study carried out on 1000 individuals at 14 days or more following onset of symptoms. The MHRA Target Product Profile requirements (as of 20.05.2020) for COVID-19 Antibody tests is a clinical study carried out on a sample size of a minimum of 200 individuals, 98% for both Clinical Sensitivity and Clinical Specificity on specimens collected 20 days or more following onset of symptoms. Clinical Sensitivity is the positive detection of COVID-19 IgG antibodies, these antibodies begin production at days 10-14 days following onset of symptoms and this increases incrementally, therefore this test exceeds the MHRA requirements

  • Knowing if you, your colleagues or your patients have had Coronavirus.
  • Providing yourself and your patients the assurance to proceed safely with the administration of treatments.
  • Helping to ensure a safe working environment.
  • Enabling you to offer additional services to your patients.

For optimum results, the test should be performed at 14 days or more following onset of symptoms. If a positive test result is obtained and there is a concern about a current infection, we advise performing a PCR Swab Test and seeking medical advice.

In light of recent MHRA guidance (published 28.05.2020) the guidance in relation to the rapid point-of-care type COVID-19 Antibody Tests such as this test remains unchanged.

The recently published guidance and changes are in relation to laboratory-based COVID-19 Antibody Tests that were originally granted MHRA approval to be used with a venous blood sample and to be carried out by a healthcare professional.

These laboratory-based COVID-19 Antibody Tests were instead marketed and sold by companies to be carried out by the patient at home (not by a healthcare professional in a professional capacity) using a finger-prick blood sample (not venous blood) and sent to the laboratory for analysis. Therefore, these tests were being used off-label and not covered by their CE certification which invalidated the granted approval.

The MHRA has therefore temporarily stopped sales of these laboratory-based tests until further validation of the sample collection kits and the sample type is carried out to support how companies wish to market their intended use.

This test is classed as an "in vitro diagnostic" medical device (IVD) and all medical devices have to be CE marked, this antibody test is CE certified and marked.

Our bespoke COVID-19 page and documents are for guidance purposes only; the responsibility remains with the practitioner at all times. It is the responsibly of the practitioner to ensure clinical good practice and public health is prioritised at all times, whilst following Public Health England recommendations.

Cookie Policy

Church Pharmacy uses cookies to improve your browsing experience. If you continue, we'll assume that you are happy to receive cookies from our website, although you can change your browser's cookie settings at any time. Find out more.

 

Back to top